Recent price action and business snapshot

Recursion Pharmaceuticals (RXRX) has drawn fresh attention after its stock closed at US$3.79. Recent moves over the past week, month, and past 3 months have prompted closer scrutiny from investors.

The US based clinical stage biotechnology company focuses on decoding biology and chemistry. It reported revenue of US$66.41 million alongside a net loss of US$559.78 million and a market value of about US$1.91b.

The recent 25.91% 7-day share price return and 11.80% 30-day share price return contrast with a year-to-date share price decline of 9.76% and a 1-year total shareholder return decline of 13.27%. This points to short-term momentum following a weaker longer-term run.

If you are looking beyond a single biotech stock, this can be a useful moment to scan a wider set of healthcare AI opportunities using the Simply Wall St screener for 40 healthcare AI stocks.

With Recursion generating US$66.41 million in revenue alongside a sizeable net loss and trading at US$3.79 with a value score of 2, is this stock underappreciated, or is the market already pricing in its future growth potential?

Most Popular Narrative: 92.4% Overvalued

The most followed narrative on Recursion puts fair value at $1.97 per share, well below the last close at $3.79, setting up a clear valuation gap to examine.

RXRX is a terrible biotech only because the INSIDERS themselves don’t believe in it! All they’re doing is milking the heck out of this doomed stock! Never seen a company where ALL they’re doing insiders are selling! Stock continues to go down every month! CEO said in 2014 that in 10 years there would be 100 new drugs! 12 years later they have ZERO 0️⃣!!! This stock went from over $40 to under $4! The hype is unbelievable! Worst biotech ever!!! Nuff said

Curious how this narrative still arrives at a specific fair value per share? Revenue assumptions, profit margins, and a future earnings multiple quietly sit at its core.

Result: Fair Value of $1.97 (OVERVALUED)

However, insider selling patterns and ongoing clinical trial uncertainty could shift sentiment quickly if new data, leadership changes, or partnership updates challenge this view of overvaluation.

Another take on value: cash flows tell a different story

While the most popular narrative pegs fair value at $1.97 per share and calls RXRX overvalued, Simply Wall St's DCF model points the other way, with an estimated future cash flow value of $9 per share. This implies the stock trades about 57.9% below that figure.

DCF models lean heavily on long range assumptions about revenue growth and future profitability, so this gap could reflect either an opportunity for patient investors or a signal that the cash flow outlook is too optimistic. Which story do you think fits RXRX better: the crowd’s narrative or the cash flow math?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Recursion Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment this split, it makes sense to look at the numbers, read the narratives, and decide quickly where you stand based on the 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If Recursion has your attention, do not stop there. Widen your watchlist with other stock ideas that fit different goals, risk levels, and income needs.

• Target future growth potential by scanning a curated list of companies trading below their estimated worth using the Simply Wall St screener for 47 high quality undervalued stocks.
• Strengthen your portfolio’s income stream by focusing on dependable payers through the Simply Wall St screener for 10 dividend fortresses.
• Protect your capital by filtering for companies with resilient finances using the Simply Wall St screener for 62 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.